Status and phase
Conditions
Treatments
About
This is an open single-arm clinical study aimed at evaluating the safety and tolerance of allogeneic γ9δ2 T cell injection in the treatment of patients with recurrent hematologic tumors after allogeneic hematopoietic stem cell transplantation.
Full description
To evaluate the safety and in vivo dynamics of allogeneic γ9δ2 T cell in the treatment of recurrent hematologic tumors after allogeneic hematopoietic stem cell transplantation patients, and to explore the appropriate therapeutic dose.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Age 12-65 (inclusive);
Patients with recurrent hematologic tumors after allogeneic hematopoietic stem cell transplantation;
Basically normal liver and kidney function (as demonstrated by the following laboratory tests prior to initial γ9δ2 T cell therapy)
No obvious hereditary disease;
Normal cardiac function, cardiac ejection index above 55%;
Women of reproductive age (15 to 49 years) must undergo a pregnancy test within 7 days before starting treatment and the result is negative, and use contraception during the clinical trial period and within 3 months after the last cell transfusion;
Sign informed consent.
Exclusion criteria
Patients with simple extramedullary recurrence;
Pregnant and lactating women;
Organ failure;
Patients with a history of solid organ transplantation;
Uncontrollable infectious diseases or other serious diseases, including but not limited to infections (such as HIV positive), congestive heart failure, unstable angina, arrhythmia, psychosis, or restricted social circumstances or those that the attending physician considers to pose unpredictable risks;
Patients with systemic autoimmune diseases or primary immunodeficiency;
Patients with allergic constitution;
Use of systemic steroid drugs;
Chronic diseases requiring the use of immunological agents or hormone herapy;
Prior treatment with any other immune cells;
Participated in similar clinical trials within 30 days;
Received radiation therapy within 4 weeks from the time of enrollment;
Researchers don't think clinical trials are appropriate for other reasons.
Primary purpose
Allocation
Interventional model
Masking
10 participants in 1 patient group
Loading...
Central trial contact
Zhu Xiaoyu, Ph.D; Sun Guangyu
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal